Fresenius Kabi intros generic Foscavir

Fresenius Kabi is offering foscarnet sodium injection in a 6000 mg / 250 mL bottle.

The medication is the generic of Foscavir. It is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome. Combination therapy with foscarnet sodium injection and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug.

“We’re pleased to offer this first-to-market generic for Foscavir in the United States, an important treatment for immune-compromised patients,” said John Ducker, president and CEO of Fresenius Kabi USA. “Fresenius Kabi is committed to providing clinicians high-quality, high-value products, at lower costs, to treat a wide variety of disease states.”